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MinireviewGene Therapy for Human
Severe Combined Immunodeficiencies
hematopoietic precursor cells in the absence of mye-
loablative treatment is indeed in the order of one cell
in a few thousands (Malech et al., 1997). In addition,
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INSERM U 429 transgenes placed under the transcriptional control of
viral LTR can be silenced in vivo (Klug et al., 2000). SomeHoˆpital Necker
149 Rue de Se`vres of these limitations have now been overcome. Progress
in this area is discussed in detail in several recently75015 Paris
France published reviews (Halene and Kohn, 2000; Sadelain et
al., 2000; Williams and Smith, 2000; Candotti, 2000).
Packaging cell lines have been designed to produce a
high titer of retroviral particles, while pseudotyping of
In principle, gene therapy is an attractive option for in-
virions with envelopes from monkey or feline retrovi-
herited blood-borne diseases, since gene transfer into
ruses substantially increases the transduction rate of
hematopoietic stem cells (HSC) with self-renewal capac-
CD34() hematopoietic precursor cells (Kelly et al.,
ity should lead to cure. In addition, though still poorly
2000). During the ex vivo infection phase, usage of cyto-
characterized, HSC can easily be retrieved in relatively
kines, i.e., flt3-ligand, stem cell factor (SCF), and mega-
large numbers in the bone marrow or by mobilization in
karyocyte differentiating factors (MGDF), enable cell di-
blood and be thus physically accessible to gene transfer.
vision without differentiation of early hematopoietic
However, several clinical trials based on gene transfer
progenitor cells. Coating of culture bags by a fibronectin
into hematopoietic cells did not lead to efficient trans-
fragment (CH296) also increases the transduction rate
duction rates of these cells (reviewed in Candotti, 2000).
by bringing together cells and viral particles (Hanenberg
The clinical grade approved vectors enabling gene inte-
et al., 1996). Finally, modification of vectors by trimming
gration into the genome of hematopoietic cells are all
silencing sequences or introducing an insulator could
derived from murine oncoretroviruses. Such vectors
enhance transgene transcription rate. Taking into ac-
were found to be effective in the transduction of murine
count these advances, it is not proper to compare results
HSC but much less so for human HSC (Miller, 1992).
of clinical trials performed very recently with those per-
Two factors account for this discrepancy. Human HSC
formed earlier.
express low numbers of membrane receptors for am-
photropic envelopes and, above all, DNA provirus-inte-
SCID Are the Model Conditions for Gene Therapygration complexes derived from such viruses do not
Despite these achievements, there is still a long way tocross the nuclear membrane of quiescent cells, the state
go before highly efficient gene transfer into human HSCof most HSC. Despite these major limitations, the issue
will be made possible in a safe setting. This is whereof gene therapy of inherited immunodeficiencies ap-
the choice of the right model for gene therapy inter-pears timely for two reasons: (1) the advent of significant
venes. Some forms of severe combined immunodefi-advances in the technology of gene transfer into hema-
ciency represent, in principle, such a model. These aretopoietic precursor cells and (2) the determination in
lethal disorders with a still partially unsatisfactory treat-the last 10 years of the genetic basis and molecular
ment, i.e., allogeneic stem cell transplantation (Buckleymechanisms of many primary immunodeficiencies.
et al., 1999; Patel et al., 2000). They are characterizedSome forms of severe combined immunodeficiency
by inherited blocks in T cell development, variably asso-(SCID) appear to be the ideal model(s) to assess gene
ciated with defects in other lymphoid lineages (Figuretherapy feasibility. This assumption is based on the po-
1). The genetic bases of many forms of SCID have nowtential selective advantage provided to lymphocyte pro-
been identified. The normal products of these genes aregenitor cells by transgene expression combined with
involved in either (1) providing survival/growth signalsthe expected long life of differentiated T cells.
to lymphocyte precursors upon c-dependent cytokine
binding, i.e., c cytokine receptor subunit, interleu-
Advances in Technology of Gene Transfer kin-7 receptor  chain, JAK-3 kinase, (2) the V(D)J re-
into Hematopoietic Precursors combination process, i.e., Rag-1, Rag-2, and Artemis (3)
Moloney retroviruses (MLV) and related oncoretrovi- signal transduction, i.e., CD45, CD3 subunits or ZAP-70
ruses are suitable for infection and integration of trans- kinase or (4) protection against cell apoptosis, i.e., en-
gene into cycling target cells. Potential risk of recombi- zymes of purine metabolism—adenosine deaminase
nation events generating replication-competent virus is (ADA) and purine nucleoside phosphorylase (PNP) (re-
prevented by using disarmed packaging cell lines (dis- viewed in Notarangelo et al., 2000).
cussed in Halene and Kohn, 2000; Sadelain et al., 2000; In theory, expression of any of these normal genes,
Williams and Smith, 2000). As stated above, however, even in a small set of lymphocyte precursor cells, should
transduction rates of human HSC by these vectors are restore the production of a large number of mature T
very low. Long-term expression of transgene in myeloid lymphocytes that will be long lived. This is based on
cells from patients who received ex vivo transduced the assumption that a selective growth advantage is
conferred to the normal gene-transduced lymphocyte
precursors. This hypothesis has received strong support1 Correspondence: fischer@necker.fr
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Figure 1. Scheme of Human Lymphocyte Development Pathway with Indication of SCID Conditions
Each arrow represents a block in lymphocytes development causing SCID. Interrupted line indicates partial block.
from unique clinical observations and experimental all positive factors minimizing potential advent of delete-
rious effects of c gene transfer. In addition, it was founddata. In two patients, one with X-linked SCID (SCID-X1,
c deficiency), the second with ADA deficiency, a natural both in in vitro gene transfer experiments in c-deficient
B cells and in an in vivo murine model that the expressiongene therapy resulted from a likely single spontaneous
reverse mutation that occurred in a T cell precursor of an abnormal endogenous c protein at cell surface
did not exert a detectable dominant-negative effect on(Bousso et al., 2000; Hirschhorn et al., 1996). It was
found in the former case that at least 1,000 T cell clones, the expression and function of the c transgene product
(Hacein-Bey et al., 1996; Otsu et al., 2001). In vitro geneas defined by the expression of differentially rearranged
TCR  chains, were generated and persisted over 2 to transfer experiments (see Fischer et al., 2000) and cor-
rection of c deficiency in several c (-) mice models5 years (Bousso et al., 2000). These results indicate that
at least 10 to 11 cell divisions of the c () T cell precur- (Lo et al., 1999; Otsu et al., 2000; Soudais et al., 2000)
positively completed a set of preclinical experimentssor occurred prior to TCR gene rearrangement. The
analysis of the immune system of this unique patient suggesting potential efficacy. A clinical protocol was
then built based on the recent advances of the technol-thus unveiled the in vivo capacity of a single T cell pre-
cursor to generate a diverse T cell repertoire (circa 1% ogy of ex vivo gene transfer into human hematopoietic
progenitor cells (see above and Cavazzana-Calvo et al.,of the normal one). Its relative stability over time (up to
the age of 5 years) comes as strong evidence to support 2000). A rate of 30% to 40% of CD34 () cell transduction
was readily achieved. A clinical trial was therefore initi-the rationale for gene therapy of SCID-X1. In parallel,
Sorrentino’s group has demonstrated that in JAK-3() ated in March, 1999. Preliminary results were reported
last year (Cavazzana-Calvo et al., 2000). In the first twomice, following ex vivo JAK-3 gene transfer into HSC,
a selective advantage was provided to JAK-3() lym- patients, there has been sustained correction of most
aspects of the immunodeficiency in the absence of anyphocyte precursors as, in the periphery, the frequency
of JAK-3() differentiated lymphocytes was found much adverse effects. Similar findings with a shorter follow
up have been observed in two additional patients, whilehigher than the frequency of transduced myeloid cells
(Bunting et al., 2000). To some extent, a similar finding treatment failed in a fifth who had splenomegaly caused
by disseminated BCG infection (S.H.-B. et al., submit-was made by Kohn et al. (1998) in an ADA gene therapy
clinical trial. ted). The pattern of c transgene integration and expres-
sion confirmed that c was necessary to induce T and
NK lymphocyte development, while it is much less soSCID-X1 (c Deficiency) as Optimal Model
for B lymphocytes. c expression was found to exertBased on this rationale, we selected SCID-X1 as the best
no impact on myeloid cell development. The efficacy ofpossible model. Indeed, besides the above mentioned
gene transfer into hematopoietic progenitor cells wasobservations, the fact that there is little c gene tran-
sufficient to generate a normal size T lymphocyte poolscription regulation, that c expression pattern is ubiqui-
in the periphery, the characteristics of which cannot betous and constitutive among the different hematopoietic
lineages, while c exerts no autonomous function, were distinguished from age-matched controls. T cell reper-
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toire diversity, the predominant presence of naive T cells of the size of the T cell pool and its repertoire and
function is, therefore, warranted.and antigen-specific T cell responses, were all within
normal range 1 year after treatment (Cavazzana-Calvo Given the low rate of circulating B cells transduction,
likely caused by competition with the pool of untrans-et al., 2000). After 6 months, lower but sustained counts
of NK cells were found, as also observed following allo- duced B cells, it is unknown whether gene therapy could
be helpful to correct the B cell deficiency observed ingeneic stem cell transplantation. B cell immunity was
also at least in part restored, although it is yet unclear many patients after haploidentical stem cell trans-
plantation.whether only transduced B cells (circa 1%) are func-
tional. Development of antigen-specific immune re-
sponses in these children has occurred, as they have SCID-X1 Gene Therapy and Thereafter?
cleared infections present prior to treatment and have Besides long-term analysis of treated cases, there is an
since grown normally without serious infections while obvious need to reproduce these results in a larger set of
free of any treatment. patients, including more cases in whom an endogenous
These preliminary results demonstrate the validity of abnormal c protein is present in lymphocyte precursors
the concept that gene therapy based on a selective as well as patients with partially preserved T cell devel-
advantage of normal gene transduced cells can work. opment (Notarangelo et al., 2000). Also, and this is not
It could also be that the selection process contributes a straightforward issue, methods for the large-scale pro-
to the maintenance of c expression, thus avoiding duction of clinical batches of vectors have to be devel-
transgene silencing, as has often been observed follow- oped. What about extension to the treatment of other
ing gene transfer with vectors in which transgene ex- immunodeficiencies? If one assumes that the most suit-
pression is controlled by the viral long terminal repeat able disease was chosen, then treatment of other condi-
(Klug et al., 2000). These results obviously raise a num- tions raises additional difficulties (for a detailed discus-
ber of questions, to understand their full significance. sion of the latter, see Candotti, 2000, and Fischer et al.,
First of all, why did previous gene therapy trials for ADA 2000). This means that further advances in gene transfer
deficiency not work while a survival selective advantage technology in hematopoietic precursor cells will be nec-
should have been provided by ADA transgene expres- essary in this setting. Note, however, that for the treat-
sion into lymphocyte precursors? Three factors can po- ment of conditions for which a selective advantage of
tentially account for this. (1) All ADA-deficient patients transduced cells is expected, a high rate of CD34 ()
received enzyme replacement therapy by weekly mus- cell transduction might not be appropriate since: (1) a
cular injections of bovine ADA coupled to polyethylene high rate of transduction is not necessary to achieve
(PEG-ADA) concomitantly with their gene therapy. This T lymphocyte development and (2) it will lead to the
metabolically efficient treatment could have much re- multiplication of the number of transgene copy integra-
duced or even abrogated the survival advantage of tions. The latter could potentially increase the risk of
transduced over nontransduced cells. (2) ADA defi- deleterious consequences of insertional mutagenesis.
ciency appears to be a much more complex disease SCID conditions with an identical or closely related dis-
than the other SCID conditions. For instance, thymic ease mechanism to SCID-X1, i.e., JAK-3 and IL-7R
epithelial cells are abnormal in ADA-deficient mice. It deficiency, are the most obvious next candidate dis-
may well be that correction of the hematopoietic-derived eases for gene therapy. Experimental gene therapy of
cells will not provide full correction of the immunodefi- JAK-3(-) mice has provided convincing results including
ciency. (3) All clinical trials were performed in the early proven efficacy in unirradiated mice (Bunting et al.,
90’s. As discussed above, many advances in gene trans- 2000). SCID conditions caused by Rag-1, Rag-2, or Ar-
fer technology have occurred since, leading to at least temis gene mutations are also worthwhile to consider,
a 10-fold gain in gene transfer efficiency. since allogeneic stem cell transplantation provides
The most important issue deals with the nature of the poorer results than for other SCID conditions. Genetic
earliest transduced cells of the SCID-X1 treated pa- deficiencies in the immune system that impair further
tients. The answer to this question will likely, at least in downstream T cell development will be more difficult to
part, determine the long-term outcome of the treatment tackle since (1) a less potent selective advantage is to
as well as extension to the treatment of other conditions. be expected and (2) considerations on transgene ex-
There are no definitive answers yet, as time together pression regulation (both spatial and temporal) will have
with a careful analysis of transgene integration sites to be addressed. In this respect however, the spectacu-
in the different hematopoietic lineages will provide the lar achievement of tissue-specific -globin expression
required information. Nevertheless, the sustained detec- in erythroid cells in  thalassemic mice represents a
tion of thymopoiesis 1 year after treatment, as well as significant advance. This result is based on the insertion
of a low percentage of transduced myeloid cells (in the in the lentiviral vector of a minimal version of the locus
order of 1‰), together with the presence of some trans- control region (LTR) of the -globin gene (May et al.,
duced CD34() cells (Cavazzana-Calvo et al., 2000), 2000).
suggests that immature pluripotent progenitor cells One can, from the above, consider that proof of princi-
have been transduced. The potential self-renewal ca- ple has been achieved in the genetic treatment of inher-
pacity of some of these progenitors is a matter of specu- ited disorders of the immune system. Much remains to
lation. These findings, together with the absence, so far, be done by combining both an in depth appraisal of
of indication of c transgene silencing, raise hope that every single disease mechanism (i.e., in other words,
a functional T cell pool could persist over a high number understanding the function of the corresponding gene
product) and development of new aspects in gene trans-of years in these patients. Careful long-term follow up
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fer technologies. It is obvious that a potentially safe use
of lentiviral vectors able to efficiently target HSC would
provide a major advance to the field (reviewed in Sade-
lain et al., 2000). Technologies of gene repair might also
become a consideration in the future.
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